Physician profile
Melissa Dodson
NPI 1306204698
$11,770.43
in general payments reported to CMS, 2019-2025
49 companies · $3,572 in 2025
The $3,572 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,145 · 2022: $2,332 · 2023: $2,050 · 2024: $2,672 · 2025: $3,572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,163 · Travel and Lodging: $2,023 · Education: $82.25 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,162.66 |
| Travel and Lodging | $2,022.60 |
| Education | $82.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,572.96 | 2023-2025 | Vercise, Wavewriter Alpha Prime 16 |
| Abbvie INC. | $2,011.13 | 2021-2025 | |
| Medtronic, INC. | $1,353.09 | 2022-2024 | Percept PC Brainsense, Activa PC |
| Neurocrine Biosciences, INC. | $615.56 | 2022-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $529.82 | 2021-2025 | Vumerity, Tysabri, Leqembi |
| Ucb, INC. | $416.69 | 2021-2025 | Briviact, Nayzilam, Rystiggo |
| Lundbeck LLC | $333.17 | 2021-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $327.47 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $270.69 | 2022-2025 | Ultomiris, Soliris |
| Sk Life Science, INC. | $265.32 | 2023-2025 | Xcopri |
| Astrazeneca Pharmaceuticals LP | $261.83 | 2021 | |
| Celgene Corporation | $255.92 | 2023-2025 | Zeposia |
| Pfizer INC. | $168.89 | 2023-2025 | |
| Lilly USA, LLC | $160.33 | 2022-2025 | Kisunla, Emgality, Amyvid |
| Mdd US Operations, LLC | $136.90 | 2025 | Gocovri |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $130.01 | 2021 | |
| Genentech USA, INC. | $124.05 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Ge Healthcare | $112.90 | 2025 | |
| Eisai INC. | $108.66 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.58 | 2023-2025 | Hyqvia, Gammagard |
| Argenx US, INC. | $107.89 | 2023-2025 | Vyvgart Hytrulo |
| Acadia Pharmaceuticals INC | $95.72 | 2025 | Nuplazid, Daybue |
| Teva Pharmaceuticals USA, INC. | $95.01 | 2022-2024 | Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $88.56 | 2022 | |
| Amneal Pharmaceuticals LLC | $85.39 | 2025 | Crexont |
| Janssen Biotech, INC. | $84.88 | 2025 | |
| Alnylam Pharmaceuticals INC. | $77.08 | 2022-2024 | Amvuttra |
| Kyowa Kirin, INC. | $75.26 | 2021-2024 | Nourianz |
| Genzyme Corporation | $74.01 | 2022-2025 | |
| Tanabe Pharma America, INC. | $70.63 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $64.28 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $51.76 | 2023-2025 | Nuedexta, Rexulti |
| Aquestive Therapeutics, INC. | $47.32 | 2022 | |
| Janssen Pharmaceuticals, INC | $43.36 | 2021 | |
| Allergan, INC. | $42.79 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $42.59 | 2021-2022 | |
| Axsome Therapeutics, INC. | $35.74 | 2025 | Symbravo |
| Ani Pharmaceuticals, INC. | $34.93 | 2025 | Purified Cortrophin Gel |
| Invivyd INC | $31.14 | 2025 | Pemgarda |
| Corium, LLC | $30.57 | 2023 | Adlarity |
| Averitas Pharma INC. | $30.00 | 2024 | Qutenza |
| Amgen INC. | $29.37 | 2021 | |
| Harmony Biosciences LLC | $29.15 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $28.18 | 2021 | |
| Aucta Pharmaceuticals, INC. | $25.32 | 2025 | Motpoly Xr |
| Neurelis, INC. | $25.31 | 2025 | Valtoco |
| Livanova USA, INC. | $23.28 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Ipsen Biopharmaceuticals, INC | $20.98 | 2024 | Dysport |
| Adamas Pharmaceuticals, INC. | $15.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Dodson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.